Back to search

Article

‘Which severe COVID-19 patients could benefit from High dose dexamethasone? A Bayesian reanalysis of a randomized clinical trial

2023-03-17

Abstract excerpt

<h4>Background: </h4> The respective benefits of high and low doses of dexamethasone (DXM) in patients with severe acute respiratory syndrome coronavirus 2 (SARS-Cov2) and acute respiratory failure (ARF) are controversial, with two large triple-blind RCTs reaching opposite conclusions. In the COVIDICUS trial, we argued against any additional benefit of high-dose dexamethasone (DXM20). We aimed to explore whether s...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
d04e4de6-d39e-5d1a-bbfa-4f1efd76284f
DOI
10.21203/rs.3.rs-2687554/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
‘Which severe COVID-19 patients could benefit from High dose dexamethasone? A Bayesian reanalysis of a randomized clinical trialDOI 10.21203/rs.3.rs-2687554/v1
Comparative Effectiveness of Dexamethasone in Treatment of Hospitalized COVID-19 Patients during the First Year of the Pandemic: The N3C Data RepositorySemantic proximity
Inferring molecular mechanisms of dexamethasone therapy in severe COVID-19 from existing transcriptomic dataSemantic proximity
Early suPAR-Guided Anakinra Treatment in COVID-19 Pneumonia: Subgroup Analyses and 90-Day Outcomes of the SAVE-MORE TrialSemantic proximity
Comparative Effectiveness and Safety of 32 Pharmacological Interventions Recommended by Guidelines for COVID-19: A Systematic Review and Network Meta-Analysis Combining 66 TrialsSemantic proximity
On Whether Therapeutic Plasma Exchange is Effective Against Severe/Critical COVID-19 PneumoniaSemantic proximity
Credible learning of hydroxychloroquine and dexamethasone effects on COVID-19 mortality outside of randomized trialsSemantic proximity
On whether therapeutic plasma exchange is an effective cure against severe/critical COVID-19 pneumoniaSemantic proximity
A novel hyperinflammation clinical risk tool, HI5-NEWS2, predicts mortality following early dexamethasone use in an observational cohort of hospitalised COVID-19 patientsSemantic proximity
Dexamethasone Ameliorates Severe Pneumonia But Slightly Enhances Viral Replication in Lung of SARS-CoV-2-Infected Syrian HamsterSemantic proximity
Adjunctive Corticosteroids for COVID-19: A Retrospective Cohort StudySemantic proximity
Clinical and Non-clinical Proof of Concept Supporting the Development of RJX As an Adjunct to Standard of Care Against Severe COVID-19Semantic proximity
A Novel Hyperinflammation Clinical Risk Tool, HI5-NEWS2, Predicts Mortality Following Early Dexamethasone Use in an Observational Cohort of Hospitalised COVID-19 PatientsSemantic proximity
Select a neighboring publication to make it the new centre.